Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005782 · ClinicalTrials.gov registry record · Phase 1
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 333
- Enrollment target
NCT03005782: Completed Phase 1 study, sponsored by Regeneron Pharmaceuticals.
NCT03005782 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 333 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (455% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03005782, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 333 participants
- Enrollment target
Study Summary
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).
Interventions
- DRUG cemiplimab
- DRUG REGN3767
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2024-04-02 |
| Phase | Phase 1 |
What the finished NCT03005782 record still lists
NCT03005782 is an interventional study that assigns participants to a tested intervention. The registered 333 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (455% higher).
The record links to 0 conditions, and to 2 interventions - of which cemiplimab is the first listed.
NCT03005782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03005782 about?
NCT03005782 is a clinical study titled "Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers". The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary o...
What is the current status of trial NCT03005782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 333 participants. The study started on 2016-11-07. Estimated completion is 2024-04-02.
What interventions are being tested in trial NCT03005782?
The interventions under investigation include: cemiplimab (DRUG), REGN3767 (DRUG).
Who is sponsoring clinical trial NCT03005782?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03005782's enrollment target sits among peer trials
333 108th of 2000 higher than 1,893 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07395687 · 333 participants · Phase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI